Harsh Shah, DO
Hematology & Oncology · Detroit, MINPI 1023456324
Payments from drug & device makers
Across 474 payments — averaging $5467.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Epizyme, Inc.$1M
- Astrazeneca UK Limited$292K
- Beigene, Ltd.$267K
- Seagen Inc.$214K
- Acerta Pharma LLC$174K
- Eli Lilly$164K
- plus $467K from 15 others
Across 5 payments — averaging $7906.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$35K
- Pfizer$4K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Epizyme, Inc. | 256 | $1,015,152 |
| Astrazeneca UK Limited | 6 | $291,621 |
| Beigene, Ltd. | 62 | $266,745 |
| Seagen Inc. | 55 | $213,821 |
| Acerta Pharma LLC | 13 | $173,548 |
| Eli Lilly | 6 | $164,273 |
| ADC Therapeutics America, Inc. | 18 | $152,461 |
| Pfizer | 15 | $150,724 |
| Incyte Corporation | 11 | $138,014 |
| Beone Medicines Ltd. | 3 | $13,443 |
| Acrotech Biopharma Inc. | 5 | $3,749 |
| E.r. Squibb & Sons, L.L.C. | 5 | $3,074 |
| Sobi, Inc | 1 | $2,670 |
| AbbVie | 2 | $1,224 |
| AstraZeneca | 7 | $394 |
| Taiho Oncology, Inc. | 4 | $378 |
| Agios Pharmaceuticals, Inc. | 1 | $127 |
| Genmab U.S., Inc. | 1 | $127 |
| Adaptive Biotechnologies Corporation | 1 | $64 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $38 |
| Novartis | 1 | $35 |
How this compares
$2,591,682 in reported general payments places this provider in the 95th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Detroit
- Hirva MamdaniDetroit$9.5M
- Jeffrey ZonderDetroit$8.2M
- Abhinav DeolDetroit$4.5M
- Igor RybkinDetroit$2.4M
- Anthony ShieldsDetroit$2.3M
- Mohammed Al HallakDetroit$1.7M
- Yusra ShaoDetroit$1.5M
- Jay YangDetroit$1.4M
- Hadeel AssadDetroit$1.2M
- Wasif SaifDetroit$885K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.